Literature DB >> 12202600

Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland.

Lena Rós Asmundsdóttir1, Helga Erlendsdóttir, Magnús Gottfredsson.   

Abstract

A nationwide study on candidemia was conducted in Iceland from 1980 to 1999. The annual incidence increased from 1.4 cases/100,000 inhabitants/year between 1980 and 1984 to 4.9 cases/100,000 inhabitants/year between 1995 and 1999 (P < 0.0001). Candidemia episodes at university hospitals increased from 0.15/1,000 admissions to 0.55/1,000 admissions (P < 0.0001). Candida albicans was the predominant species responsible (64.4%). The national import of fluconazole increased approximately fourfold during the second half of the study, but increased resistance to this agent was not observed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202600      PMCID: PMC130691          DOI: 10.1128/JCM.40.9.3489-3492.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  C Viscoli; C Girmenia; A Marinus; L Collette; P Martino; B Vandercam; C Doyen; B Lebeau; D Spence; V Krcmery; B De Pauw; F Meunier
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

2.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

3.  Candidaemia in an Australian teaching hospital: relationship to central line and TPN use.

Authors:  I Stratov; T Gottlieb; R Bradbury; G M O'Kane
Journal:  J Infect       Date:  1998-03       Impact factor: 6.072

4.  Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society.

Authors:  D L Yamamura; C Rotstein; L E Nicolle; S Ioannou
Journal:  CMAJ       Date:  1999-02-23       Impact factor: 8.262

5.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

6.  National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units.

Authors:  M S Rangel-Frausto; T Wiblin; H M Blumberg; L Saiman; J Patterson; M Rinaldi; M Pfaller; J E Edwards; W Jarvis; J Dawson; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

7.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

Authors:  K A Marr; K Seidel; T C White; R A Bowden
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

8.  Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals.

Authors:  D J Sullivan; T J Westerneng; K A Haynes; D E Bennett; D C Coleman
Journal:  Microbiology       Date:  1995-07       Impact factor: 2.777

9.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

10.  Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group.

Authors:  P Sandven; L Bevanger; A Digranes; P Gaustad; H H Haukland; M Steinbakk
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

View more
  49 in total

1.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.

Authors:  M A Pfaller; A Espinel-Ingroff; R N Jones
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  Candidemia in Norway (1991 to 2003): results from a nationwide study.

Authors:  Per Sandven; Lars Bevanger; Asbjørn Digranes; Hanne H Haukland; Turid Mannsåker; Peter Gaustad
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 4.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 5.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

6.  Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern.

Authors:  K M T Astvad; H K Johansen; B L Røder; F S Rosenvinge; J D Knudsen; L Lemming; H C Schønheyder; R K Hare; L Kristensen; L Nielsen; J B Gertsen; E Dzajic; M Pedersen; C Østergård; B Olesen; T S Søndergaard; M C Arendrup
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

7.  Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.

Authors:  Ingi Lee; Neil O Fishman; Theoklis E Zaoutis; Knashawn H Morales; Mark G Weiner; Marie Synnestvedt; Irving Nachamkin; Ebbing Lautenbach
Journal:  Arch Intern Med       Date:  2009-02-23

8.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.

Authors:  Guy St-Germain; Michel Laverdière; René Pelletier; Pierre René; Anne-Marie Bourgault; Claude Lemieux; Michael Libman
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

Review 10.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.